GSK (LON:GSK) Receives “Hold” Rating from Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Wednesday,Digital Look reports. They presently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft’s target price points to a potential upside of 6.61% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. Citigroup dropped their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Wednesday, July 29th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of GBX 2,048.57.

GSK Stock Performance

GSK stock opened at GBX 1,876 on Wednesday. The company has a 50 day moving average price of GBX 1,939.08 and a 200-day moving average price of GBX 1,998.43. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82. GSK has a fifty-two week low of GBX 1,288.61 and a fifty-two week high of GBX 2,282. The company has a market capitalization of £75.15 billion, a PE ratio of 15.93, a P/E/G ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, equities analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insider Buying and Selling at GSK

In other GSK news, insider Jonathan Symonds purchased 1,550 shares of the stock in a transaction on Friday, June 19th. The stock was acquired at an average price of GBX 1,935 per share, with a total value of £29,992.50. Also, insider Jeannie Lee purchased 802 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were acquired at an average price of GBX 5,069 per share, for a total transaction of £40,653.38. Over the last ninety days, insiders acquired 3,618 shares of company stock worth $13,481,942. 0.20% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.